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ABSTRACT
Acne keloidalis nuchae (AKN) is a chronic
inflammatory condition that leads to fibrotic
plaques, papules and alopecia on the occiput
and/or nape of the neck. Traditional medical
management focuses on prevention, utilization
of oral and topical antibiotics, and intralesional
steroids in order to decrease inflammation and
secondary infections. Unfortunately, therapy
may require months of treatment to achieve
incomplete results and recurrences are
common. Surgical approach to treatment of
lesions is invasive, may require general
anesthesia and requires more time to recover.
Light and laser therapies offer an alternative
treatment for AKN. The present study
systematically reviews the currently available
literature on the treatment of AKN. While all
modalities are discussed, light and laser therapy
is emphasized due to its relatively unknown role
in clinical management of AKN. The most
studied modalities in the literature were the
1064-nm neodymium-doped yttrium
aluminum garnet laser, 810-nm diode laser,
and CO2 laser, which allow for 82–95%
improvement in 1–5 sessions. Moreover, side
effects were minimal with transient erythema
and mild burning being the most common.
Overall, further larger-scale randomized head to
head control trials are needed to determine
optimal treatments.
Keywords: Acne keloidalis nuchae; Hair
disorders; Lasers; Systematic review; Therapy;
Treatment
INTRODUCTION
Acne keloidalis nuchae (AKN) is a chronic
inflammatory condition that leads to scarring
of the hair follicles, development of keloid-like
papules and plaques, and scarring alopecia on
the nape of the neck and occipital scalp. Studies
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report the incidence of AKN being between
0.45% and 9%, and occurring mostly in
darkerskinned races with curly or kinky hair
[1–5]. While this condition most commonly
occurs in blacks, AKN can also be seen in
Caucasians [29]. Moreover, the condition has a
predilection for men, occurring 20 times more
frequently than in women [6], and starts after
adolescence. The natural course of disease starts
with the early formation of inflamed papules
with marked erythema. Secondary infection can
lead to pustules and abscess formation in some
cases. Over time, continued inflammation leads
to pronounced fibrosis and keloid formation
with coalescence of the papules into large
plaques and nodules. Later stages of
presentation include chronic scarring and/or
scarring alopecia without active inflammation.
While the exact underlying pathogenesis of
AKN is not known, the two predominant
theories suggest skin injury and the existence
of aberrant immune reactions as the underlying
causes. Skin injuries from irritation, occlusion,
trauma, friction and hair cutting practices have
all been implicated as risk factors for the
development of AKN [7–10]. The characteristic
curvature of afro-textured hair has also been
implicated in inciting AKN, but no clinical or
pathologic evidence exists to substantiate this
[11]. Furthermore, some have proposed that
AKN is due to an immune reaction that leads to
the cicatricial alopecia. Upon histological
examination, a mixed, neutrophilic and
lymphocytic infiltration has been observed
[36]. In this theory, intrafollicular antigens
attract inflammatory cells to the follicle,
resulting in damage to the sebaceous gland
and follicular wall. This in turn leads to rupture
of the follicle and release of antigens into the
hair follicle that precipitates the inflammatory
process and epithelial destruction leading to
fibrosis [12].
Traditional management of the disease
focuses on preventing disease progression,
including avoidance of mechanical irritation
from clothing and use of antimicrobial
cleansers to prevent secondary infection [13].
Treatment usually involves use of topical,
intralesional or systemic steroids in
combination with retinoids and/or antibiotics
to decrease inflammation [14, 15]. When the
disease progresses from early to late stage,
surgical excision and skin grafting may be
performed, which require long periods of
healing. Recent advances in light and laser
therapies offer an alternative treatment option
for AKN. However, the potential of these
modalities in the treatment for AKN has not
been comprehensively reviewed. This review
explores medical, surgical and light therapies
for AKN and discusses the clinical implications.
METHODS
A literature review of the National Library of
Medicine database, PubMed, was performed on
July 6, 2015 (Fig. 1). The following search terms
were used individually: ‘‘Acne Keloidalis
Nuchae’’, ‘‘Folliculitis Keloidalis Nuchae’’,
‘‘Acne Keloidalis’’ and ‘‘Folliculitis Keloidalis’’.
Search results were cross-checked with the
Scopus database using the same search terms.
Initial searching returned 558 articles. Only
articles written in English were included for
further review. The titles and abstracts of the
articles were independently reviewed by two
authors for relevance to the treatment of AKN.
Articles were included if they were original
studies and contained suitable background
information, clinical presentation, and
treatment information for AKN. A total of 22
studies were included, containing 85 total
patients treated with different modalities. The
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majority of studies were case reports/case series.
This article is based on previously conducted
studies and does not involve any new studies of




A total of 15 studies were found utilizing
medical and surgical treatments for AKN (see
Tables 1, 2). Medical management included the
use of topical or oral antibiotics, corticosteroids,
retinoids, topical fusidic acid and topical urea.
Medical management showed varying degrees
of improvement, with complete resolution in
one case. Overall, surgical approaches to
treating AKN resulted in a drastic
improvement of the condition, though there
was some recurrence of disease and the cosmetic
results were variable. Additionally, there was
one report on radiotherapy and dermabrasion.
Medical Treatment
The earliest case of medical management of
AKN was reported by Dinehart et al. [16] who
treated two females with intralesional
triamcinolone and tetracycline (oral),
respectively. There was marked improvement
in both patients. The patient receiving
Fig. 1 Systematic search of PubMed returned 558 total studies. After review of titles, abstracts, and full-text, 22 studies were
included in this review
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triamcinolone had no new lesions at 6 months,
though many small papules remained; the
patient receiving tetracycline had dramatic
improvement, including a decrease in pain,
size and purulence of the lesions. Conversely,
Harris et al. [17] reported a case of AKN in a
male professional football player.
Triamcinolone and antibiotics were
administered with little improvement seen
until the patient’s offseason, at which time the
condition spontaneously resolved. Medical
management has also been a
suitable therapeutic approach for AKN
associated with keratosis follicularis spinulosa
decalvans [14, 18]. Two cases have been
reported, both involving young men (aged 18
and 27 years, respectively). Goh et al. [14]
utilized oral isotretinoin (20 mg, 0.25 mg/
kg/day) after failed attempts with minocycline
(oral), doxycycline (oral), mometasone furoate
(topical) and triamcinolone acetate
(intralesional injection). Within weeks,
dramatic improvement was seen in the lesions
on the vertex of the patient’s scalp.
Inflammation on the neck responded less
dramatically, while the patient’s follicular
tufting/follicular hyperkeratotic papules
exhibited no change. Maintenance on low
dose isotretinoin (20 mg every 2–3 days) kept
the patients vertex inflammation under control,
seen at 1-year follow-up. Janjua et al. [18] used
combination topical fusidic acid and oral
cefadroxil (500 mg twice daily for 2 weeks) to
treat a patient. Antibacterial therapy was
repeated as necessary. There was marked
improvement in the lesions of the scalp and
nuchal area at 6 months, though some
hypertrophic scarring and tufts remained.
Overall, medical management seemed to
improve the condition, though complete
resolution was not seen. Thus, the modality
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Surgical Treatment
Surgical excision was described in eight studies
[4, 19–25]. In one report, six males with AKN
refractory to numerous medications, both
topical and systemic, underwent surgical
excision of the involved areas to muscle fascia
or deep subcutaneous tissue [4]. Healing by
second intention was allowed, which resulted in
an average closure time of 6–8 weeks. Good
cosmetic results were achieved in four patients
(those receiving horizontal elliptical excision
including the posterior hairline), while
recurrence occurred in two patients. Another
study reported surgical excision and healing by
second intention performed on five patients
[21]. Although scarring was significant, the
cosmetic results were acceptable in all
patients. At 2 months to 4 years follow-up,
contractures did not limit function nor did
disease recur. In two similar studies by Bajaj
et al. [19] and Etzkorn et al. [22], a total of three
cases of AKN were surgically excised with
healing by second intention. Excellent
cosmetic results and no recurrences were seen
(follow-up at 7, 14 and 18 months,
respectively).
Electrosurgery is another treatment option
for AKN. This modality allows for excision of
the lesion with simultaneous coagulation of
small vessels similar to laser excision with CO2.
In one case utilizing electrosurgery, healing by
second intention resulted in complete closure at
5 weeks with good wound contracture and a
small flat scar [20]. No recurrence was observed
at 8 months postoperative. In the largest study
to date, Gloster et al. [23] performed surgical
excision in 25 patients with AKN. Twenty
patients underwent excision with layered
closure in 1 stage, 4 underwent 2-stage
excision with layered closure and one
underwent excision with second-intention
healing. Treated areas were subjectively scored
from poor (1) to excellent (4) by both the
patient and physician. At 1-year follow-up, the
results were scored with an average overall score
of 3.8. Five patients, however, developed
hypertrophic scarring and 15 patients had
mild recurrences of tiny pustules and papules
during the first 4 months that were
subsequently treated with topical and
intralesional steroids.
An alternative surgical approach was taken
in a case of AKN in a 40-year-old male using a
semilunar 400-ml tissue expander [24].
Postoperative infiltrations were performed at
14 days and each week thereafter, expanding
the tissue by 380 ml. At the 46th post-operative
day, the expander was removed and the affected
area was closed. Local radiotherapy was
administered weekly until 1000 rad was
reached. An excellent cosmetic result was
achieved, with no recurrence of AKN and no
signs of the ‘‘stretch-back’’ phenomenon at
2-year follow-up. The case was complicated by
infection at 20 days post-operation that was
successfully treated with cephalexin.
A variety of combined treatments have also
been reported for the treatment of AKN. Layton
et al. [26] compared intralesional triamcinolone
with cryosurgery using the spot freeze
technique with two 15-s freeze–thaw cycles.
Overall, the assigned scores of pre-therapy
palpability (used as an indicator of severity)
correlated with the response to treatment
(P\0.04) and cryosurgery provided better
results for more vascular lesions (P\0.03). At
8-week follow-up, there were sustained
improvements in the lesions. Dermabrasion
was attempted in one case of AKN in a
38-year-old male [27]. After three sessions,
there was approximately a 50% reduction in
lesion size. However, the patient refused
additional sessions and was subsequently
Dermatol Ther (Heidelb) (2016) 6:363–378 371
referred for surgical excision. In one particularly
refractory case of AKN reported by Cayetano
et al. [28], the patient was treated for 5 years
with cycles of cryotherapy, topical antibiotics
(clindamycin 1% solution), oral antibiotics
(doxycycline 100 mg/day), infiltrations of
intralesional triamcinolone, oral isotretinoin
(50 mg/day) and oral sulphone (100 mg/day).
The patient also received electro-curettage and
partial excision with primary closure. With
continued worsening, the patient underwent
radiotherapy at 3 Gy per session for ten sessions
on alternating days (total dose of 30 Gy).
Complete alopecia was seen at 2 months after
radiotherapy which resolved 4 months later,
except in the area of the original keloid
plaque. The lesion eventually flattened,
leading to a small residual scar and good
cosmetic results. No recurrence was seen at
20-months follow-up.
Light and Laser Therapy
Lasers utilized included the CO2 laser, 1064-nm
neodymium-doped yttrium aluminum garnet
(Nd:YAG) laser, 59-nm pulse dye laser (PDL),
and 810-nm diode laser (Table 3). The earliest
study by Kantor et al. used a CO2 laser for
surgical excision for late stage treatment of AKN
[29]. By using a CO2 laser with a focused beam,
fibrotic areas in six black patients and two white
patients could be removed in an
outpatient-based setting with local anesthesia.
Moreover, none of the patients who were
treated using this modalityhad a relapse. Two
patients in the study with early AKN were
treated with laser evaporation using the
unfocused beam setting with 130–150 J/cm2
fluence with three to four passes in one
session. However, relapse occurred in both
cases. In another case, CO2 laser evaporation
with the same fluence setting was utilized in a
Caucasian male who had developed AKN while
on chronic cyclosporine treatment for a heart
transplant. The patient’s AKN relapsed shortly
after treatment forcing the patient to undergo
surgical intervention [30]. In a third case
involving a Caucasian male, CO2 laser excision
was coupled with a single postoperative
intralesional injection of triamcinolone acetate
(5 ml of 25 mg/ml) and three radiotherapy
sessions of 400 cGY [31]. The first of which
was given on the same day following the
procedure. The patient developed a few
satellite lesions that were treated with CO2
laser excision. The patient had a full recovery
and regrowth of hair in the treated region.
In a case series by Shah [32], 2 males were
treated using a 810-nm diode laser who had
previous treatment failures with oral
antibiotics, intralesional and topical steroids.
After 4 treatment sessions of 23–26 J/cm2
fluence with 100 ms pulses, the patients had a
90% and 95% clearance, respectively, that was
maintained at 6-months follow-up. Treatments
were tolerated with only transient mild
burning.
Dragoni et al. [33] treated a single
fair-skinned 23-year-old Caucasian male using
a 595-nm PDL with 6.5 J/cm2 fluence and
0.5 ms pulse. The results, however, were
transient and lesions returned in 1 month.
Subsequently, a 1064-nm Nd:YAG laser with
101–120 J/cm2 fluence was used for four
sessions, which lead to a significant
improvement in scarring that was clinically
apparent. Esmat et al. [34] also used a
1064-nm Nd:YAG laser to treat patients with
AKN in a pilot study using 35–45 J/cm2 fluence
over five sessions. Patients between the ages of
22 and 54 years old with Fitzpatrick skin types 3
and 4 were treated. Significant improvements
were seen after the third treatment and in 82%
of the lesions after the 5th session. Moreover,
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biopsies taken from the treated area showed
significant reductions in the inflammatory
infiltrate after the final treatment. No
recurrences of lesions were noted at 1-year
follow-up.
Light therapy consisted of the use of a 290-
to 320-nm targeted UVB (tUVB) halide arc lamp
(Table 3). The most recent study by Okoye et al.
[35] used tUVB light to treat 11 male patients
using a split-scalp designed study. Initial UVB
dosage was determined using the minimal
erythema dose that ranged between 0.23 and
0.48 J/cm2. Treatment dosing was increased by
20% per week until the end of 8 weeks and was
maintained at the same dose for an additional
8 weeks. The control side of the scalp was
treated after the 8th week according to the
same protocol until the end of the study at
16 weeks. Treatments were tolerated well with
only mild burning and erythema. Patients were
given two to three treatments per week. A
significant improvement was noted on the
treated side by 34% at 8 weeks and 49% at
16 weeks. The results were maintained at
2-months follow-up. In addition to clinical
improvements, an up-regulation of matrix
metalloproteinases MMP1, MMP9, TGFB1 and
COL1A1 were seen by histology, indicating
higher rates of extracellular matrix turnover.
DISCUSSION
AKN is a common condition, which can lead to
significant scarring, alopecia and negatively
impact on quality of life. The pathogenesis of
AKN is not completely understood, though
trauma and/or immune reactions are thought
to play a role. Other factors in disease
progression have been suggested, such as a
familial component or a cutaneous
manifestation of metabolic syndrome [25, 27].
However, further investigation to elucidate the
underlying pathogenesis is required.
To date, a number of treatments have been
used to treat this condition, from topical
antibiotics to surgical excision of fibrotic
lesions. Traditional medical management can
require months of daily treatment and may
relapse after discontinuation of treatment [6].
Light and laser treatments can offer an
alternative to medical management that is
noninvasive and generally well tolerated. CO2
laser excision can be used as monotherapy in
place of surgical excision of AKN lesions
without the need for general anesthesia or in
combination with intralesional steroids and
radiotherapy. However, CO2 vaporization is
not very effective in treating AKN because
lesions recur shortly after treatment and
because of the incidence of scarring in
dark-skinned individuals following CO2
vaporization.
Medical management includes intralesional
injection and/or topical corticosteroids, topical
or oral antibiotics (particularly tetracyclines),
and retinoids. Oral isotretinoin (20 mg,
0.25 mg/kg/day) was shown to improve
inflammation, but had minimal effect on
follicular tufting/follicular hyperkeratotic
papules. Amongst the medical modalities,
patients receiving intralesional steroids had
the most dramatic improvement.
Surgical excision, while extensively discussed
in the literature, should be reserved for more
extensive and refractory lesions. Healing by
second-intention was the most common
method used postoperatively. Cryosurgery
provided a varied response to lesions, though
may be best suited for more vascular lesions
[26]. Surgical or cryosurgical treatment with
secondary intention healing is the most
effective treatment modality for AKN;
however, the outcomes are still not optimal.
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Of the 41 patients treated by surgical excision
that were included in this review, 17 had mild
recurrence. Additionally, scarring is the major
concern with a surgical approach, though use of
a horizontal ellipse encompassing the posterior
hairline resulted in good to excellent cosmesis
by allowing the surgical scar to be hidden in the
newly formed hairline. Dermabrasion was
reported in one case and did not achieve
complete resolution. Radiotherapy was used in
two cases of AKN that were refractory to
extensive and aggressive treatment [28, 31].
While this modality resulted in complete
resolution with no recurrence; radiotherapy
should be reserved for the most severe and
refractory cases, considering the side effects of
such treatment.
The two most extensively studied light and
laser therapies include treatment with a
1064-nm Nd:YAG laser and tUVB light.
Among the light and laser modalities, the
1064-nm Nd:YAG laser and 810-nm diode
laser appears to be the most effective for
treating AKN. Results from these small studies
are promising with therapeutic responses in the
range of 82–95%. While tUVB therapy was well
tolerated with only mild burning and erythema,
it was not as effective as the 1064-nm Nd:YAG
laser, with clinical improvements in the range
of 34–49%.
Overall, laser and light therapies for AKN
appear to work by decreasing the inflammatory
response and/or destroying the hair follicle,
which appears to be a nidus that prolongs the
vicious cycle of inflammation and fibrosis seen
with AKN. Moreover, in the case of tUVB
therapy, there is a modulation in expression of
matrix metalloproteinases, suggesting that
extracellular matrix turnover is enhanced
which may act to improve lesions [35].
CONCLUSIONS
Medical management of AKN can be used in
mild cases. Surgical excision should be reserved
for more extensive lesions with prominent
fibrosis. However, concern for post-surgical
scarring must be considered. Overall,
management of AKN with light and laser
treatments looks promising with 1064-nm
Nd:YAG, 810-nm Diode, and CO2 lasers that
allow for 82–95% improvement in 1–5 sessions.
Moreover, side effects were minimal with
transient erythema and mild burning being
the most common. However, the studies are
primarily based on case series and small pilot
studies. Thus, larger-scaled randomized
controlled trials with long-term follow-up are
needed to effectively assess these treatments.
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